The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Plasma extracellular vesicles as biomarkers of primary versus acquired resistance to immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors.
 
Scott Strum
No Relationships to Disclose
 
Diego de Miguel Perez
Patents, Royalties, Other Intellectual Property - WO2018215686 - ISOLATION OF CELLS OF EPITHELIAL ORIGIN CIRCULATING IN PERIPHERAL BLOOD Patent is not being exploited
 
Sofia Genta
Honoraria - Amgen
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Merck
 
Sam Saibil
No Relationships to Disclose
 
Marcus Butler
Honoraria - Bristol-Myers Squibb; Medison; Merck; Novartis; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Adaptimmune; Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; IDEAYA Biosciences; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; LaRoche Posay; Medison; Merck; Novartis; Novartis; Pfizer; Regeneron; Sanofi; Sun Pharma
Research Funding - Merck (Inst); Novartis Canada Pharmaceuticals Inc (Inst); Takara Bio (Inst)
Expert Testimony - Merck
 
Aaron Hansen
Consulting or Advisory Role - Astellas Pharma; Bayer; Eisai; Janssen; Merck
Research Funding - Advancell (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Macrogenics (Inst); Merck (Inst); Roche/Genentech (Inst); Seagen (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Lawson Eng
No Relationships to Disclose
 
Lillian Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca; Daiichi Sankyo/UCB Japan; Gilead Sciences; GlaxoSmithKline; Incyte; LTZ Therapeutics; Marengo Therapeutics; Medicenna; Merck; Navire; Nerviano Medical Sciences; Pangea; Pangea; Relay Therapeutics; Roche; Seagen; Tubulis GmbH; Voronoi Health Analytics
Research Funding - 23andMe (Inst); Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); LegoChem Biosciences (Inst); Loxo/Lilly (Inst); Marengo Therapeutics (Inst); Medicenna (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Takara Bio (Inst)
 
Christian Rolfo
Leadership - ELSEVIER; ESMO; European School Oncology; IASLC; International Society of Liquid Biopsy
Consulting or Advisory Role - Abbvie; Amgen; Aptitude Health; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cor2Ed; Daiichi Sankyo Europe GmbH; Diverse Health Hub; EMD Serono; FLASCO; Guardant Health; Guardant Health; HMP Education; IDEOlogy Health; Imagene AI; Intellisphere; InVitae; Janssen Scientific Affairs; LUNGEVITY; Medical Education Consortium; MedStar Health; Merck Serono; MJH Live Events; Novartis; Novocure; Regeneron; ROCHE
Speakers' Bureau - Guardant Health; Roche Molecular Diagnostics
Research Funding - Lung Cancer Research Foundation
(OPTIONAL) Uncompensated Relationships - Guardant Health
 
Anna Spreafico
Consulting or Advisory Role - Alentis Therapeutics; Bristol-Myers Squibb; GlaxoSmithKline; Merck
Research Funding - Alentis Therapeutics (Inst); Alkermes (Inst); ALX Oncology (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Nubiyota (Inst); Pfizer (Inst); Replimune (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Symphogen (Inst); Teva (Inst); Treadwell Therapeutics (Inst)